艾地苯醌联合奥拉西坦治疗老年阿尔茨海默病的疗效观察

目的 分析艾地苯醌联合奥拉西坦治疗老年阿尔茨海默病患者的临床疗效。方法 选择2016年7月-2018年7月开滦总医院收治的老年阿尔茨海默病患者57例作为研究对象，根据治疗方法差异将患者分为对照组（30例）和观察组（27例）。对照组口服奥拉西坦胶囊，0.8 g/次，3次/d。观察组在对照组基础上口服艾地苯醌片，30 mg/次，3次/d。3个月为1疗程，两组均治疗2个疗程。观察两组患者的临床疗效，同时比较两组治疗前后的蒙特利尔认知评估量表（MoCA）评分、日常生活能力量表（ADL）评分和神经精神科量表（NPI）评分。结果 治疗后，观察组总有效率为85.19%，显著高于对照组的60.00%，两组比较具有统计学意义（P<0.05）。随着治疗时间延长，两组患者MoCA评分均显著提升（P<0.05），但观察组MoCA评分明显高于同时期对照组（P<0.05）。随着治疗时间延长，两组患者ADL评分均显著降低（P<0.05），但观察组ADL评分明显低于同时期对照组（P<0.05）。治疗后，观察组患者NPI评分低于治疗前（P<0.05），且观察组治疗后NPI评分显著低于对照组（P<0.05）。结论 艾地苯醌联合奥拉西坦治疗老年阿尔茨海默病效果显著，且能有效改善患者认知及行为能力，改善精神症状，同时用药安全性较高。

Clinical observation of idebenone combined with oxiracetam in treatment of senile Alzheimer's disease

Objective To analyze the clinical effect of idebenone combined with oxiracetam in treatment of senile Alzheimer''s disease. Methods Fifty-seven elderly patients with Alzheimer''s disease admitted to Kailuan General Hospital from July 2016 to July 2018 were selected as study subjects, and the patients were divided into control group (30 cases) and observation group (27 cases) according to the differences in treatment methods. Patients in the control group were po administered with Oxiracetam Capsules, 0.8 g/time, and 3 times daily. Patients in the observation group were po administered with Idebenone Tablets on the basis of control group, 30 mg/time, 3 times daily. Three months for one course of treatment, the two groups were treated for two courses. The clinical efficacy in two groups was observed, and the MoCA, ADL, and NPI scores in two groups before and after treatment were compared. Results After treatment, the total effective rate of the observation group was 85.19%, which was significantly higher than 60.00% in the control group, and the comparison between two groups was statistically significant (P<0.05). With the extension of treatment time, the MoCA score in two groups was significantly increased (P<0.05), but the MoCA score in the observation group was significantly higher than that of the control group (P<0.05). With the extension of treatment time, The ADL score in two groups significantly decreased (P<0.05), but the ADL score of the observation group was significantly lower than that of the control group at the same time (P<0.05). After treatment, the NPI score of patients in the observation group was lower than that before treatment (P<0.05), and the NPI score of patients in the observation group was significantly lower than that of the control group (P<0.05). Conclusion Idebenone combined with oxiracetam in treatment of senile Alzheimer''s disease has a significant effect, and can effectively improve the cognitive and behavioral ability of patients, improve mental symptoms, at the same time, the drug safety is higher.